Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment

被引:30
|
作者
van Geffen, Erica C. G. [1 ]
van Hulten, Rolf [1 ]
Bouvy, Marcel L. [2 ]
Egberts, Antoine C. G. [1 ]
Heerdink, Eibert R. [1 ]
机构
[1] Univ Utrecht, Fac Sci, Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands
关键词
adverse effects; nonadherence; selective serotonin-reuptake inhibitors;
D O I
10.1345/aph.1K516
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Studies have shown that up to 38% of patients who start treat ment with antidepressants fill only a single prescription at the pharmacy, I apparently not accepting treatment. OBJECTIVE: To determine characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor (SSRI) treatment. METHODS: A retrospective, study was conducted in 37 community pharmacies in the Netherlands; patients who presented a prescription from a general practitioner (GP) for a newly started SSRI treatment were selected. Nonaccepters were defined as patients who filled only one SSRI prescription; patients who received at least 3 fills of an SSRI prescription were defined as accepters. Patient characteristics were obtained from automated dispensing records and from questionnaires. Areas of evaluation included sociodemographics, disease, and treatment. Nonaccepters were asked their reasons for not filling second prescriptions. RESULTS: Of the patients who started SSRI treatment, 22.0% were nonaccepters, filling only a single prescription. Fifty-seven nonaccepters and 128 accepters were included in our analysis. Nonacceptance was more common among patients with a low level of education (OR 2.6; 95% CI 1.1 to 5.9) and in patients who reported nonspecific symptoms like fatigue, stress, and restlessness as the reason for SSRI use (OR 2.7; 95% CI 1.4 to 5.5). Of the nonaccepters, 29.8% (n = 17) did not start SSRI use, and 70.2% (n = 40) discontinued SSRI use within 2 weeks. Fear of adverse effects and the actual occurrence of adverse effects were main reasons for not accepting SSRI treatment. Of the nonaccepters, 55.0% discontinued treatment without informing their GPs. CONCLUSIONS: Acceptance of SSRI treatment is a decisive moment in a patient's adherence to treatment initiated by his or her GP and deserves more attention; GPs and pharmacists should address treatment issues, especially in groups at risk for nonacceptance.
引用
收藏
页码:218 / 225
页数:8
相关论文
共 50 条
  • [2] Characteristics and reasons associated with non-acceptance of selective serotonin reuptake inhibitor treatment
    van Geffen, Erica Cg
    van Hulten, Rolf
    Bouvy, Marcel L.
    Egberts, Antoine C. G.
    Heerdink, Eibert R.
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 658 - 658
  • [3] Hyponatraemia associated with the use of a selective serotonin-reuptake inhibitor in an older patient
    Schouten, WEM
    Sepers, JM
    AGE AND AGEING, 2001, 30 (01) : 94 - 94
  • [4] Hyponatremia associated with selective serotonin-reuptake inhibitors
    Petrykiv, S.
    De Jonge, L.
    Arts, M.
    EUROPEAN PSYCHIATRY, 2017, 41 : S758 - S758
  • [5] Selective serotonin-reuptake inhibitor-induced movement disorders
    Gerber, PE
    Lynd, LD
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (06) : 692 - 698
  • [6] Selective serotonin-reuptake inhibitors for the treatment of hot flashes
    De Sloover Koch, Y
    Ernst, ME
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (7-8) : 1293 - 1296
  • [7] Duloxetine: A balanced and selective norepinephrine- and serotonin-reuptake inhibitor
    Westanmo, AD
    Gayken, J
    Haight, R
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (23) : 2481 - 2490
  • [8] Selective serotonin-reuptake inhibitors in the treatment of premature ejaculation
    Moreland, AJ
    Makela, EH
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (7-8) : 1296 - 1301
  • [9] Clastogenicity of selective serotonin-reuptake inhibitors
    Bozkurt, G
    Abay, E
    Ates, I
    Karabogaz, G
    Ture, M
    Savran, FO
    Palanduz, S
    Temocin, K
    Algunes, C
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2004, 558 (1-2) : 137 - 144
  • [10] Movement disturbances associated with the use of selective serotonin-reuptake inhibitors
    Leo, RJ
    ANNALS OF PHARMACOTHERAPY, 1998, 32 (06) : 712 - 714